post-burn leukoderma. Leukoderma, not elsewhere classified
Conditions
Interventions
Intervention 1: After preparing melanocyte suspension according to patent No.139250140003003854, dermabrasion performed by high- speed motor dermabrador and Suspension will be transferred to the desir
Treatment - Devices
After preparing melanocyte suspension according to patent No.139250140003003854, dermabrasion performed by high- speed motor dermabrador and Suspension will be transferred to the desired location. It
After preparing melanocyte suspension according to patent No.139250140003003854, Suspension by Erbium YAG laser( lotus II, laseropteck compay, Seoul, Korea, 2012) with wave length 2940 nm, spot size 3
Sponsors
Vice Chancellor for research of Isfahan University of Medical Sciences.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age =18 years; Non-pregnant and non-breast feeding women; without history of chronic diseases, skin cancer, drug sensitivity/sever allergic reactions, immun deficient, organ transplant or steroid treatment; The absence of coagulopathy or anticoagulation therapy; No evidence of hypertrophic burn scar; The total area treated is >40 cm2. Exclusion criteria: Previous treatment of skin lesions; Active systemic infection.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Repigmentation scales. Timepoint: one, three and six months after the end of treatment. Method of measurement: by dermatology Colleagues blinded to the randomization. | — |
Secondary
| Measure | Time frame |
|---|---|
| Edema, Erythema, Infection and Dyspigmentation. Timepoint: One week, ane month, three months and six months after treatment. Method of measurement: Eye Clinical Evaluation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Marzieh Matin
Skin disease and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Ira
Outcome results
None listed